Resistance mutation info of target

Target General Information
Target ID T89534
Target Name Estrogen receptor (ESR1) Target Info
Gene Name ESR1
Species Homo sapiens
Uniprot ID ESR1_HUMAN
Sequence MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV [Hom
o sapiens]
Drug Resistance Mutation and Corresponding Drugs
Mutation Info Missense: D538G
Drugs
Drug Name Endocrine Therapy Drug Info [1]
Targeted Disease Breast Cancer
Mutation Prevalence 9 out of 28 patients
Mutation Info Missense: E380Q
Drugs
Drug Name Tamoxifen Drug Info [2], [3], [4]
Targeted Disease Breast Cancer
Mutation Prevalence 11 out of 76 patients
Mutation Info Missense: L536-D538 > P
Drugs
Drug Name Endocrine Therapy Drug Info [1]
Targeted Disease Breast Cancer
Mutation Prevalence 1 out of 28 patients
Mutation Info Missense: L536Q
Drugs
Drug Name Endocrine Therapy Drug Info [2]
Targeted Disease Breast Cancer
Mutation Prevalence 1 out of 11 patients
Mutation Info Missense: P535H
Drugs
Drug Name Tamoxifen Drug Info [2], [3], [4]
Targeted Disease Breast Cancer
Mutation Info Missense: Y537C
Drugs
Drug Name Endocrine Therapy Drug Info [3], [5], [1]
Targeted Disease Breast Cancer
Mutation Prevalence 4 out of 28 patients
Mutation Info Missense: Y537N
Drugs
Drug Name Endocrine Therapy Drug Info [5]
Targeted Disease Breast Cancer
Mutation Prevalence 4 out of 270 patients
Mutation Info Missense: Y537S
Drugs
Drug Name Endocrine Therapy Drug Info [5]
Targeted Disease Breast Cancer
Mutation Prevalence 5 out of 270 patients
Reference
REF 1Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther. 2015 Nov 11;8:3323-8. doi: 10.2147/OTT.S92443. eCollection 2015.
REF 2Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013 Dec;45(12):1446-51. doi: 10.1038/ng.2823. Epub 2013 Nov 3.
REF 3ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3.
REF 4Emergence of constitutively active estrogen receptor- mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.
REF 5Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015 Dec;166(6):540-553.e2. doi: 10.1016/j.trsl.2015.09.003. Epub 2015 Sep 14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.